MedTrace Logo

Comparison of Pimecrolimus Cream 1% Twice-Daily to Once-Daily Dosing in the Management of Atopic Dermatitis in Pediatric Subjects

NCT00139581 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2008-04-23

No results posted yet for this study

Summary

This study is not being conducted in the United States.

To investigate the relative efficacy of pimecrolimus cream 1% applied twice daily (b.i.d.) versus once daily (o.d.) in preventing the progression to disease "relapse".

Conditions

Interventions

DRUG

Pimecrolimus

Pimecrolimus cream 1 % applied twice daily (b.i.d.)

DRUG

Pimecrolimus

Pimecrolimus cream 1 % applied once daily (o.d.) and placebo applied once daily (o.d.)

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharma AG · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
2 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-09-30
Completion
2005-09-30

Countries

  • Switzerland

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00139581 on ClinicalTrials.gov